Val66Met Polymorphism in BDNF Has No Sexual and : Evidence From an Updated Meta-Analysis of Case–Control Studies and High-Throughput Genotyping CohortsAPOE: Evidence From an Updated Meta-Analysis of Case–Control Studies and High-Throughput Genotyping Cohorts ε4 Status-Based Dimorphic Effects on Susceptibility to Alzheimer’s Disease: Evidence From an Updated Meta-Analysis of Case–Control Studies and High-Throughput Genotyping Cohorts
Some studies showed that Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) conveys susceptibility to Alzheimer’s disease (AD) in females only. However, the confounding effects of some risk factors for AD were omitted in these studies. The aim of this meta-analysis comprising 19 604 patients with AD and 26 333 controls was to reexamine the association between Val66Met and AD by conditioning the effects of age, sex, and/or apolipoprotein E (APOE) ε4 status. In agreement with the previous meta-analysis, Val66Met was associated with AD in females without confounding adjustment (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.03-1.14; P = .003). Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57). This comprehensive meta-analysis with the largest sample size demonstrated no association could be observed between Val66Met and AD in general or by dividing samples based on sex or APOE ε4.